Onyedika Ilonze is a Cardiology physician. OpenAlex indexes 116 publications with 430 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1801 N. Senate Blvd
Suite 2000
Indianapolis, IN 46202
Telephone
317-962-9700Provider last certified this registry record 10 Mar 2025.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202529 payments$29,447openpaymentsdata.cms.gov ↗
- Bayer Healthcare Pharmaceuticals Inc.Program year202510 payments$14,143openpaymentsdata.cms.gov ↗
- BridgeBio Pharma, Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
54.1%Beta blocker10.3%Metoprolol Succinate42%Carvedilol37%Metoprolol Tartrate12%Propranolol Hcl10%Part D<11 patientsStatin9.6%Atorvastatin Calcium52%Pravastatin Sodium29%Rosuvastatin Calcium20%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
15.1%SGLT2 inhibitor5.1%Jardiance80%Farxiga20%Part D<11 patientsPotassium supplement4.9%Potassium Chloride86%Klor-Con M2014%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
7.2%Calcineurin inhibitor6.1%Tacrolimus76%Cyclosporine Modified24%Part D<11 patientsKinase inhibitor1.1%Sirolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes With Femoral IABP in Heart Failure and Acute Myocardial Infarction-Related Cardiogenic Shock
Journal of Cardiac Failure
2025 - An overview of the association between socioeconomic deprivation and heart failure
Heart Failure Reviews
2025 - Impact of Comorbidity Burden on Outcome in Patients with Cardiogenic Shock: A Cardiogenic Shock Working Group analysis
European Journal of Heart Failure
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”